Literature DB >> 8229759

Discriminative-stimulus effects of the low efficacy mu agonist nalbuphine.

E A Walker1, A M Young.   

Abstract

The discriminative stimulus effects of nalbuphine were studied in 15 male Sprague-Dawley rats trained to discriminate 3.2 mg/kg of nalbuphine from saline under a fixed-ratio 15 schedule of food delivery. Cumulative doses of nalbuphine produced nalbuphine lever responding at doses of 1.0 to 10 mg/kg and rate-suppressing effects at doses of 3.2 to 32 mg/kg. Experiments to evaluate the contribution of opioid receptor activity suggested that the stimulus effects of nalbuphine were mediated through mu systems, inasmuch as mu agonists (etorphine, fentanyl, morphine, buprenorphine, GPA 1657 and nalorphine) produced nalbuphine lever responding, whereas kappa agonists [EKC and U-50,488H (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl] benzeneacetamide methanesulfonate hydrate)] and nonopioids (d-pentazocine, d-amphetamine and ketamine) produced saline lever responding. dl-Pentazocine produced nalbuphine lever responding in one-half the rats tested. Both high and low efficacy agonists produced nalbuphine lever responding, but the antagonist naltrexone produced predominantly saline lever responding. Increasing the training dose of nalbuphine by a 0.50 log unit failed to alter the potency of nalbuphine or any other compound to produce nalbuphine lever responding, suggesting that these training doses produce a maximum amount of stimulation at the mu receptor. Naltrexone antagonized the discriminative stimulus but not the rate-decreasing effects of nalbuphine, suggesting that only the discriminative stimulus effects of nalbuphine are mediated by a mu opioid mechanism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8229759

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.

Authors:  Lance R McMahon
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; Aneetha Halikhedkar; JodiAnne Wood; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2013-09-05       Impact factor: 4.530

Review 3.  Role of training dose in drug discrimination: a review.

Authors:  Ian P Stolerman; Emma Childs; Matthew M Ford; Kathleen A Grant
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

4.  Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.

Authors:  Sarah L Withey; Roger D Spealman; Jack Bergman; Carol A Paronis
Journal:  J Pharmacol Exp Ther       Date:  2019-08-14       Impact factor: 4.030

5.  Co-administration of nalbuphine attenuates the morphine-induced anxiety and dopaminergic alterations in morphine-withdrawn rats.

Authors:  Rahul Raghav; Raka Jain; Tony G Jacob; Anju Dhawan; Tara S Roy
Journal:  Psychopharmacology (Berl)       Date:  2021-03-02       Impact factor: 4.530

6.  Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.

Authors:  David R Maguire; Charles P France
Journal:  Eur J Pharmacol       Date:  2016-05-13       Impact factor: 4.432

7.  Chronic Intermittent Sucrose Consumption Facilitates the Ability to Discriminate Opioid Receptor Blockade with Naltrexone in Rats.

Authors:  David C Jewett; Donisha S N K Liyanagamage; Mark A Vanden Avond; Molly A B Anderson; Kyleigh A Twaroski; Morgan A Marek; Kimberly F James; Tapasya Pal; Anica Klockars; Pawel K Olszewski; Allen S Levine
Journal:  Nutrients       Date:  2022-02-22       Impact factor: 5.717

8.  Pharmacokinetic Study of Nalbuphine in Surgical Patients Undergoing General Anesthesia with Varying Degrees of Liver Dysfunction.

Authors:  Xiao-Nan Gao; Xu-Yang Nie; Jing-Lin Gao; Tian-Fang Heng; Yu-Qi Zhang; Li Hua; Ya-Qi Sun; Zhang-Ying Feng; Ming-Xia Wang; Li Jia
Journal:  Drug Des Devel Ther       Date:  2022-07-26       Impact factor: 4.319

Review 9.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.